Using the Surveillance, Epidemiology, and End ResultseMedicare database, we assessed overall survival (OS) among renal cell carcinoma patients who had initiated first-line targeted therapy. OS was significantly longer in the late (2010-2012) versus early (2006-2009) targeted therapy era. Positive (nephrectomy, pazopanib vs. sunitinib or sorafenib) and negative (higher tumor grade and lung, bong, or liver metastases) OS prognostic factors were identified. Background: The real-world survival outcomes and prognostic factors among patients receiving first-line targeted therapy for advanced renal cell carcinoma (aRCC) are not well known. Patients and Methods: Adult patients diagnosed with RCC and treated with first-line targeted therapy were identified from the Surveillance, Epidemiology, and End ResultseMedicare database (January 1, 1993 to December 31, 2012). The patients were grouped into early (2006-2009) or late (2010-2012) targeted therapy era cohorts by the year of the first-line targeted therapy initiation. Overall survival (OS) was measured from first-line targeted therapy initiation and compared between the 2 cohorts using Kaplan-Meier analyses. The prognostic factors for OS were assessed using a multivariable-adjusted Cox model. Results: A total of 604 and 641 aRCC patients (mean age, 68 years; w60% male in both cohorts) initiated first-line targeted therapy during the early and late targeted therapy eras, respectively. OS was significantly longer in the late than in the early targeted therapy era. Higher tumor grades (hazard ratio [HR], 1.61; 95% confidence interval [CI], 1.31-2.00) and lung (HR, 1.27; 95% CI, 1.06-1.53), bone (HR, 1.37; 95% CI, 1.13-1.66), and liver (HR, 1.42; 95% CI, 1.10-1.84) metastases were associated with significantly shorter OS. Previous nephrectomy (HR, 0.55; 95% CI, 0.42-0.72) and pazopanib as first-line targeted therapy relative to sorafenib (HR, 0.56; 95% CI, 0.37-0.85) or sunitinib (HR, 0.65; 95% CI, 0.44-0.95) were associated with significantly longer OS. Conclusion: The results of these real-world analyses suggest progress in aRCC management and identified positive (nephrectomy, pazopanib vs. sunitinib or sorafenib) and negative (higher tumor grade and lung, bone, or liver metastasis) prognostic factors among patients receiving first-line targeted therapy.
Introduction
Renal cell carcinoma (RCC) represents 80% to 85% of primary renal neoplasms. 1 In 25% to 33% of patients, RCC will be metastatic at the initial diagnosis, and a further 20% to 40% of patients undergoing treatment for localized disease will develop metastases. [2] [3] [4] Cytokine therapies were the standard of care for advanced RCC (aRCC) in the 1990s. However, although they produced complete remission in 6% to 8% of patients, these therapies were limited to a subset of patients able to tolerate the cytokine toxicity profiles. [5] [6] [7] During the past few decades, improvements in therapy, surgery, and noninvasive tumor imaging have doubled the 5-year survival rate of RCC patients, 8 resulting in a decrease in the death rate for RCC since the late 1990s, despite an increase in its incidence. 9 In particular, targeted therapies such as vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors have prolonged overall survival (OS) relative to treatment with cytokines in patients with aRCC. [10] [11] [12] The need for alternative therapies for cytokine-resistant RCC prompted the first targeted therapies approved by the US Food and Drug Administration, beginning in 2005 with sorafenib, a VEGFR-TKI. 13 In 2006, another VEGFR-TKI, sunitinib, was approved, 14 followed by the mTOR inhibitor temsirolimus in 2007. 15 A second wave of targeted therapy innovation occurred beginning in 2009, with approval of the mTOR inhibitor everolimus, 16 the humanized anti-VEGF monoclonal antibody bevacizumab, 17, 18 and the VEGFR-TKI pazopanib. 19 Axitinib, a selective VEGFR inhibitor, was approved in 2011. 20 Since the advent of targeted therapies, the median survival of patients with metastatic RCC has increased from 10 to 20 months. [10] [11] [12] However, it is poorly understood whether the trend toward increasing OS has continued with the introduction of newer targeted therapies. The prognostic factors associated with longer OS have potentially changed since the adoption of treatment paradigms focusing on targeted therapy. Some major prognostic factor models currently used as predictive tools to aid in RCC treatment decision-making, such as the Memorial Sloan Kettering Cancer Center (MSKCC) prognostic score, 21 were developed in the age of cytokines and could benefit from re-evaluation in the age of targeted therapy. For example, a 2013 retrospective study of OS among aRCC patients used Surveillance 23 However, that study did not assess OS prognostic factors. 23 Thus, a need remains to define the patient, disease, and treatment factors associated with survival in the targeted therapy era, 24 in particular, regarding VEGFR-TKIs, the most commonly used first-line targeted therapies for aRCC. 25 To assess whether an increasing trend in OS exists and to identify the predictive factors associated with OS among RCC patients in real-world practice with greater granularity, the present study used real-world drug-specific data corresponding to aRCC patients who initiated first-line targeted therapy during the early (2006) (2007) (2008) (2009) and late (2010-2012) targeted therapy eras.
Patients and Methods

Data Source
The present study used data from the SEEReMedicare database (January 1, 1993 to December 31, 2012), 26 provided by the Na- 
Patient Selection Criteria
Adult patients (aged ! 18 years) with a diagnosis of RCC were identified in the SEEReMedicare data using the International Classification of Diseases for Oncology, 3rd edition, codes C64 and C65, with only a clinically relevant histologic subtype (ie, clear cell, papillary, or chromophobe; codes 8310, 8260, and 8317, respectively). Patients were included in the study if they had first initiated targeted therapy (ie, sorafenib, sunitinib, pazopanib, axitinib, everolimus, temsirolimus, or bevacizumab) after a diagnosis of RCC and between January 1, 2006 (start of Medicare part D data availability) and December 31, 2012 (data cutoff; the codes used to identify the drugs used are listed in Supplemental Table 1 ; available in the online version). The date of the first-line targeted therapy initiation was defined as the index date. The patients were also required to have had ! 6 months of continuous health plan enrollment before the index date and recorded surgical status and cause of death (if deceased). Patients were followed up from the initiation of the first-line targeted therapy to the first date of health plan disenrollment or the end of data availability.
The included patients were stratified into 2 cohorts according to the date of initiation of first-line targeted therapy: (1) early targeted therapy era (2006-2009); or (2) late targeted therapy era (2010) (2011) (2012) . A subset of patients who initiated first-line targeted therapy with the VEGFR-TKIs approved as first-line treatment for aRCC (pazopanib, sorafenib, or sunitinib) was also identified. Owing to the relatively recent approval of axitinib (January 27, 2012), the sample size of patients receiving axitinib as first-line targeted therapy was too small to be included in the analysis.
Patient Characteristics and Outcomes
The patient demographic and clinical characteristics assessed at the initial RCC diagnosis included age, sex, race/ethnicity, tumor grade, tumor size, tumor histologic subtype, nephrectomy status, and the e574 -Clinical Genitourinary Cancer August 2017
Real-world Outcomes in Advanced Renal Cell Carcinoma presence of distant metastasis. Comorbidities (ie, cardiovascular disease, hypertension, chronic pulmonary disease, diabetes, renal failure, and liver disease) and the presence of specific metastatic sites (ie, lung, lymph node, bone, and liver) were assessed in the 6 months before the index date (baseline period). The codes used to identify the comorbidities are listed in Supplemental Table 2 (available in the online version). Lung, liver, lymph node, bone, and liver metastases were identified using the International Classification of Diseases, 9th edition, Clinical Modification (codes 197.0x, 196.xx, 198.5x, 197 .7x, respectively).
OS was defined as the interval from the index date to the date of death from any cause and assessed for the early and late targeted therapy era cohorts. Separately, OS was assessed for patients who had initiated pazopanib, sorafenib, or sunitinib as first-line targeted therapy.
Statistical Analysis
The patient characteristics were assessed and compared between the early and late targeted therapy era cohorts and among the first-line targeted therapy (ie, pazopanib, sorafenib, and sunitinib) cohorts using Wilcoxon rank-sum tests for continuous variables and c 2 tests for categorical variables. OS was assessed and compared using KaplanMeier analysis with log-rank tests. In the OS analysis, patients were censored at the first date of the end of health plan enrollment or the end of data availability. To assess the prognostic factors associated with OS, multivariable Cox proportional hazards models adjusting for the available patient characteristics and first-line targeted therapy were created. All statistical analyses were conducted using SAS, version 9.3 (SAS Institute, Inc, Cary, NC), software.
Results
Of 111,037 patients with a diagnosis of RCC, 49,632 had RCC with a clinically relevant histologic subtype ( Figure 1 ). Of these, 1245 eligible patients initiated first-line targeted therapy after diagnosis, including 604 patients in the early targeted therapy era 
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The baseline demographic and clinical characteristics, including tumor grade, histologic type, and metastatic sites during the baseline period, were similar between the early and late targeted therapy era cohorts ( Table 1 ). The average age was approximately 68 years, and approximately 60% of the patients were male in both cohorts. Compared with the early targeted therapy era cohort, a greater proportion of patients in the late targeted therapy era cohort had hypertension and renal failure (P < .05 for both) and a smaller proportion of patients were of a race other than white and had distant metastases at RCC diagnosis (P < .05 for both).
The baseline characteristics of the patients across the first-line targeted therapy cohorts (pazopanib, sorafenib, and sunitinib) were also largely similar, with a few significant differences (Table 2) . Compared with patients receiving pazopanib, more patients receiving sorafenib had a tumor grade of 1 or 2 (30.3% vs. 44.0%, respectively; P ¼ .031), and fewer patients receiving sorafenib had metastases in the lymph nodes (18.0% vs. 9.3%; P ¼ .041), cardiovascular disease (71.9% vs. 45.1%; P < .001), or renal failure (43.8% vs. 29.7%; P ¼ .021) in the 6 months before the initiation of targeted therapy. Additionally, a lower percentage of patients receiving sunitinib had cardiovascular disease compared with those receiving pazopanib (50.8% vs. 71.9%; P < .001).
The late targeted therapy era cohort had significantly longer OS (median, 23.4 months) relative to the early targeted therapy era cohort (median, 16.7 months; log-rank test, P < .01; Figure 2 ). In the analysis of the prognostic factors (Table 3) , higher tumor grades (grade 3 or 4) were associated with significantly shorter OS compared with lower tumor grades (grades 1 or 2; hazard ratio [HR], 1.61; 95% confidence interval [CI], 1.31-2.00). Metastases in the lung (HR, 1.27; 95% CI, 1.06-1.53), bone (HR, 1.37; 95% CI, 1.13-1.66), and liver (HR, 1.42; 95% CI, 1.10-1.84) were also associated with significantly shorter OS. Previous nephrectomy was associated with significantly longer OS (HR, 0.55; 95% CI, 0.42-0.72). Additionally, treatment with pazopanib as first-line targeted therapy was associated with significantly longer OS compared with treatment with either sorafenib (HR, 0.56; 95% CI, 0.37-0.85) or sunitinib as firstline targeted therapy (HR, 0.65; 95% CI, 0.44-0.95). These findings were consistent with the Kaplan-Meier analysis results ( Figure 3) showing that first-line targeted therapy with pazopanib was associated with longer OS (median, 19.6 months) compared with sunitinib (median, 17.3 months; log-rank test, P < .05) and sorafenib (median, 17.2 months; log-rank test, P ¼ .06).
Discussion
The present study of the real-world outcomes of patients with aRCC who initiated targeted therapy used drug-specific data from Medicare part D in the linked SEEReMedicare database to expand on previous research reporting significantly longer survival times in the era of targeted therapy versus the era of cytokine therapy. 11, 23 Improvement in survival has been attributed to the evolution of the standard of care from immunotherapies (eg, interleukin-2 and interferon [IFN]-alfa) with considerable toxicity 27 to targeted agents (eg, VEGFR-TKIs and mTOR inhibitors) with greater efficacy and lower toxicity. As a result, although the median OS was reported to be w13 months in a 2002 meta-analysis of IFN-alfa clinical trials, 21 the median OS associated with targeted therapies could be twice as long, 28 with survival past 5 years not uncommon. 29 The present study assessed OS during the establishment of targeted therapy for aRCC at greater granularity by dividing the period into early (2006-2009) and late (2010-2012) targeted therapy eras. In our comparison of aRCC patients who first initiated targeted therapy during these eras, the median OS was significantly longer in the later era than in the early targeted therapy era, suggesting that the better survival had resulted from greater facility by the treating physicians in the use of targeted therapy. Real-world Outcomes in Advanced Renal Cell Carcinoma
The development of prognostic models for use in the targeted therapy era is of high importance, because many of the existing models (eg, MSKCC and International Metastatic Renal Cell Carcinoma [IMDC] scoring systems) were created for treatment of aRCC with cytokines. The MSKCC model, based on a large cohort of patients with metastatic RCC enrolled in clinical trials and treated with IFN-alfa, 21 is the most widely used of these models. The adverse prognostic factors in the MSKCC model include an interval from diagnosis to treatment of < 1 year, 30 Karnofsky performance status (KPS) of < 80%, 31 serum lactate dehydrogenase levels > 1.5 times the upper limit of normal, corrected serum calcium > 10 mg/dL, serum hemoglobin less than the lower limit of normal, previous radiotherapy, and > 1 metastatic site. 32 The adverse prognostic factors for OS in the IMDC model include anemia, thrombocytosis, neutrophilia, KPS < 80%, and < 1 year from diagnosis to first-line targeted therapy. The IMDC model has been validated in a population of mRCC patients receiving next-line targeted therapy after progression during first-line therapy. 33 The patients who received cytoreductive nephrectomy have also been reported to have better IMDC prognostic profiles for OS; patients with < 4 IMDC prognostic factors were found likely to benefit from nephrectomy. 34 In the present prognostic factors analysis, significantly shorter OS among patients with aRCC treated with targeted therapy was associated with higher tumor grades and metastases in the lung, bone, and liver. These findings are consistent with the results from several other studies originating from the era of cytokine therapy, which also noted that metastases in the bone, 35 [39] [40] [41] The survival time generally decreased with higher tumor grades, similar to our findings. Significantly longer OS was associated with previous nephrectomy, which was also noted in 2 randomized trials of patients using cytokine therapy and thus selected in the initial MSKCC criteria 42, 43 and in several observational studies. 37, 44, 45 In 2002, nephrectomy was replaced with the time from diagnosis to the initiation of therapy in the MSKCC scoring system, 21 
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which was, in turn, removed in 2004. 46 However, the development of new therapeutic regimens for aRCC since the advent of these traditional models merits reconsideration of the current prognostic factors. With a small sample size, treatment with pazopanib as first-line targeted therapy for aRCC was associated with significantly longer OS relative to sunitinib or sorafenib. A phase III randomized clinical trial (COMPARZ [pazopanib vs. sunitinib in the treatment of locally advanced and/or metastatic RCC]) compared the safety and efficacy of pazopanib with those of sunitinib as first-line targeted therapy in terms of OS, progression-free survival (PFS), quality of life, and adverse events. 47 That study noted similar OS and PFS for the 2 therapeutic agents. Pazopanib was associated with fewer adverse events and better quality of life measures. This finding was also reported by the PISCES trial (randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib vs. sunitinib in patients with metastatic RCC) of patient preference for pazopanib versus sunitinib 48 and in an ad hoc time-withoutsymptoms analysis of the COMPARZ trial. 49 Pazopanib has also been associated with longer OS and PFS compared with sunitinib among poor-risk patients with mRCC. 50 A retrospective medical record review of mRCC patients at a single center with ! 3 MSKCC negative prognostic factors determined that patients using pazopanib experienced OS and PFS nearly twice the OS and PFS of those using sunitinib. 50 Notwithstanding the results of these retrospective studies suggesting a survival benefit with pazopanib, level 1 evidence has continued to support the survival equivalence of pazopanib and sunitinib. Regarding the comparative survival advantage of pazopanib over sunitinib observed in the present study, it is possible that the equivalent OS reported in the COMPARZ trial 47 for pazopanib and sunitinib might not extend to physicians who did not participate in the clinical trial. Also, patient outcomes could differ in real-world practice compared with the outcomes in clinical trials. For the physicians captured in the present data set, pazopanib might indeed offer a survival advantage owing to its more predictable and manageable toxicity profile. 47, 48 Future research is warranted using alternative real-world data sources, such as the National Cancer Database, prospective multiinstitutional registries or databases, and other claims databases (eg, 100% Medicare database), to further evaluate the present findings. Although our analysis focused on targeted therapies approved for first-line use, additional studies could extend the analysis to targeted therapies that can be used in the first-line setting, such as temsirolimus and axitinib, and extend the present analysis to subsequent lines of therapy. The present study did not include patients with sarcomatoid RCC, although studies are needed to assess whether OS has improved for patients with this more aggressive form of RCC in the targeted therapy era. 
Study Limitations
The interpretation of the results of the present study should be considered in light of several limitations. First, although claims data comprise a large and valid data sample from a real-world setting, the present study was subject to the limitations inherent to retrospective observational studies using claims data. Namely, administrative claims data only contain diagnostic and procedure codes recorded for reimbursement purposes, retrospective databases can be subject to coding errors or data omissions, and patients might not have used the recorded medication as prescribed after filling a prescription. Thus, the assessment of metastatic sites relies on the diagnostic codes recorded for reimbursement purposes, and the treatment initiation dates are approximate. The National Cancer Institute advised the presence of limitations with the current approach of assessing metastatic sites in the SEEReMedicare database; thus, the reported statistics for lung, lymph node, bone, and liver metastases during the baseline period should be interpreted with caution. Second, all patients in the sample initiated target therapy and thus were assumed to have advanced disease, because targeted therapies are indicated for treatment of aRCC. However, it was not possible to confirm the cancer stage for all the patients, because some patients were diagnosed with nonede novo metastatic disease, and the SEER database does not capture information on disease progression. The National Cancer Institute has emphasized this limitation for analyses of SEEReMedicare database. Third, data on several prognostic characteristics identified in the MSKCC and IMDC risk scoring systems, 30, 32 for example KPS and laboratory values, were not available in the present data. The sample size for patients using pazopanib was small (n ¼ 89), and the follow-up duration was relatively short (data were available until December 31, 2012). Future real-world studies using larger sample sizes, longer followup periods, and more integrated data sources could be considered to reassess the present findings.
Conclusion
In the present real-world study using the SEEReMedicare database, OS improved over time among patients with aRCC who had initiated a targeted therapy. Higher tumor grades and lung, bone, and liver metastases were associated with significantly shorter OS, and previous nephrectomy and treatment with pazopanib as the first-line targeted therapy relative to sunitinib or sorafenib were associated with significantly longer OS. The present findings suggest progress in the management of aRCC and have identified prognostic factors among patients treated with first-line targeted therapy.
Clinical Practice Points
Improvements in therapy, surgery, and tumor imaging have doubled the 5-year survival rate of patients with RCC in the past 50 years, despite an overall increase in incidence in the United States. The transition from cytokine treatments to targeted therapies has improved OS; however, a pressing need remains to better define the patient and disease factors associated with survival using realworld data that integrates information on targeted therapies for aRCC. Using the SEEReMedicare database, we assessed OS for aRCC patients who initiated targeted therapy during 2006 to 2009 (early targeted therapy cohort) or 2010 to 2012 (late targeted therapy cohort), and identified the prognostic factors for OS. Patients in the late targeted therapy cohort had significantly longer OS. Higher tumor grades and lung, bone, and liver metastases were associated with significantly shorter OS, and previous nephrectomy and pazopanib as first-line targeted therapy relative to sunitinib or sorafenib were associated with significantly longer OS. Our data contribute valuable information regarding OS associated with first-line targeted therapy used for aRCC, provide realworld validation of several prognostic factors noted in clinical settings, and could assist clinicians in choosing the optimal therapy for patients with aRCC according to their individual prognostic factors. 
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